GlaxoSmithKline and five other major drugmakers have partnered with the UK government to launch world's first venture capital fund exclusively for research on dementia worth $100 million to find new cures for the disease. More than 40 million people suffer from dementia globally, but there are currently no medicines to prevent or cure the conditions due to the brain's complexity. 